Further Data Confirms POLB 001’s Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS) Market opportunity estimated to be greater than US$1 billion
Further Data Confirms POLB 001’s Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS) Market opportunity estimated to be greater than US$1 billion
Key Senior Members of Former Amryt Pharma Leadership Team join Poolbeg Pharma Poolbeg team boosted by highly experienced executives with track record of success